Drug intelligence / Profile preview

tramadol + paracetamol

Development stage
Unknown
Lead developer
Fornix BioSciences
Modality
Small Molecules
Administration
Oral
01

Overview

Fornigesic is a branded generic combination analgesic marketed by Fornix Healthcare, an Indian pharmaceutical company. It is primarily formulated as a fixed-dose combination of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg), although a single-ingredient tramadol injection is also available under the same brand name. Tramadol is a centrally acting synthetic opioid that provides analgesia through a dual mechanism: it acts as a weak agonist at the mu-opioid receptor and inhibits the neuronal reuptake of norepinephrine and serotonin, thereby enhancing descending inhibitory pain pathways. Paracetamol (acetaminophen) is a non-opioid analgesic and antipyretic that is thought to inhibit prostaglandin synthesis, particularly within the central nervous system. The combination of these two agents provides a synergistic effect, offering effective management for moderate to severe acute and chronic pain with a potentially improved safety profile compared to higher doses of single-agent opioids.

Brand names
Fornigesic
Other names
tramadol hydrochloride + paracetamoltramadol + acetaminophentramadol hydrochloride + acetaminophen
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on tramadol + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tramadol + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call